Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Immune response gene 1 (Irg1) is prominently upregulated during the early phase of macrophage immune response to lipopolysaccharide (LPS) stimulation, concomitant with pronounced inflammatory activity. Prior investigations have identified Irg1 as one of the most rapidly and significantly upregulated immune-related genes in the teleost fish model following pathogenic challenge, suggesting its pivotal role in teleost immune responses. Herein, we investigated how Irg1 modulates early (12 h) inflammatory responses in head kidney-derived macrophages of Oreochromis niloticus (Nile tilapia). Our results reveal widespread distribution of Irg1 across 11 healthy O. niloticus tissues, with the highest expression observed in the spleen, followed by the head kidney and gills. Furthermore, dynamic upregulation of Irg1 expression was evident within immune-related tissues (head kidney and spleen) during a 72 h period following in vivo stress. We successfully expressed and purified the recombinant OnIRG1 protein ((r)OnIRG1) and established a macrophage model with OnIrg1 knockdown. At the onset of the cellular immune response (12 h post-LPS stimulation) the up-regulated Irg1 was found to inhibit A20 (an NF-κB negative regulatory), which activated the NF-κB signaling pathway and facilitating the expression of subsequent downstream inflammatory factors. Overall, these findings not only affirm the highly conserved structure and function of Irg1, but also broaden our comprehension of its role in teleost cellular immune regulation, emphasizing its significance in immune modulation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dci.2025.105411DOI Listing

Publication Analysis

Top Keywords

immune response
16
irg1
8
nf-κb signaling
8
role teleost
8
head kidney
8
cellular immune
8
immune
7
irg1 mediates
4
mediates inhibition
4
inhibition a20-triggered
4

Similar Publications

Microglia, the resident immune cells of the central nervous system (CNS), are involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), and Parkinson's disease (PD). 14-3-3 proteins act as molecular hubs to regulate protein-protein interactions, which are involved in numerous cellular functions, including cellular signaling, protein folding, and apoptosis. We previously revealed decreased 14-3-3 levels in the brains of human subjects with neurodegenerative diseases.

View Article and Find Full Text PDF

TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8 T cells via lysosome-dependent degradation of TCF-1.

Mol Ther

September 2025

Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address:

The reduction of TCF-1 during CD8 T cell exhaustion leads to attenuated antitumor activity and diminished responsiveness to immune checkpoint inhibitors. However, how TCF-1 is downregulated remains unclear. Here, we showed that during CD8 T cell exhaustion, lnc-SUMF2-8, induced by transcription factor TOX, can bind to cytosolic TCF-1, and direct it to the lysosome for degradation.

View Article and Find Full Text PDF

Nature-inspired IL-1 targeted therapy to treat chronic inflammatory diseases.

Mol Ther

September 2025

Department of Medicine, UMass Chan Medical School, Worcester, MA, USA; Department of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA, USA; Horae Gene Therapy Center, UMass Chan Medical School, Worcester, MA, USA; Li Weibo Institute for Rare Diseases Research, UMass Chan Medic

The interleukin (IL)-1 pathway is a key mediator of inflammation and innate immune responses. Its dysregulation contributes to rheumatoid arthritis (RA) and autoinflammatory diseases (AIDs). In this study, we develop a recombinant adeno-associated virus (rAAV)-based gene therapy to deliver an inflammation-inducible, secreted human IL-1 receptor antagonist (sIL-1Ra) as a complementary approach to existing IL-1 blockers.

View Article and Find Full Text PDF